Amlodipine and celecoxib and Larotrectinib Capsules
Determining the interaction of Amlodipine and celecoxib and Larotrectinib Capsules and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Larotrectinib may increase the blood levels and effects of amLODIPine. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects during treatment. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with larotrectinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. In study subjects, coadministration of midazolam, a sensitive CYP450 3A4 substrate, with larotrectinib 100 mg twice daily increased midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) by 1.7-fold each compared to administration of midazolam alone. The Cmax and AUC of 1-hydroxymidazolam, the main metabolite of midazolam, were both increased by 1.4-fold.
MANAGEMENT: Concomitant use of larotrectinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids. If coadministration is required, patients should be monitored carefully for increased adverse reactions of these drugs and dosage reduction of the concomitant CYP450 3A4 substrate considered if necessary.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Vitrakvi (larotrectinib)." Bayer Pharmaceutical Inc, West Haven, CT.
Generic Name: amlodipine / celecoxib
Brand name:
Synonyms: Amlodipine and celecoxib (Oral), Amlodipine and Celecoxib
Generic Name: larotrectinib
Brand name: Vitrakvi
Synonyms: Larotrectinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Amlodipine and celecoxib-Larotrectinib Oral Solution
- Amlodipine and celecoxib-Larotrectinib Sulfate
- Amlodipine and celecoxib-Lartruvo
- Amlodipine and celecoxib-Larynex
- Amlodipine and celecoxib-Laryng-O-Jet
- Amlodipine and celecoxib-Laryngesic
- Larotrectinib Capsules-Amlodipine and olmesartan
- Larotrectinib Capsules-Amlodipine and Olmesartan Medoxomil
- Larotrectinib Capsules-Amlodipine and perindopril
- Larotrectinib Capsules-Amlodipine and telmisartan
- Larotrectinib Capsules-Amlodipine and valsartan
- Larotrectinib Capsules-Amlodipine Besylate